Retatrutide
Also known as: LY3437943, GGG tri-agonist
Retatrutide is an investigational triple receptor agonist (GLP-1, GIP and glucagon) being studied in clinical trials for metabolic conditions. It is not approved for use anywhere.
- Category
- Metabolic / GLP-1
- Reported half-life
- Reported ~6 days in early trial data; not fully established
- Common forms
- Investigational injectable (clinical-trial setting), Research-grade vials (not approved)
- Research status
- Investigational GLP-1/GIP/glucagon tri-agonist still in clinical trials. Not approved by the TGA or any other regulator at the time of writing.
- Last updated
- 21 June 2026
Claimed effects
The following effects are reported or claimed by users and in early research. They are not established medical facts and many are not supported by large human trials.
- Reported in trials to support substantial weight reduction in study participants
- Reported to improve blood-glucose markers in study populations
- Reported to reduce appetite via combined gut-hormone signalling
How it is reported to work
Retatrutide is described as a single molecule that activates three receptors at once: GLP-1, GIP and the glucagon receptor. This combination is proposed to influence insulin secretion, appetite, gastric emptying and energy expenditure. These mechanisms are reported from ongoing clinical research rather than established as a marketed therapy.
Background
Retatrutide is an investigational triple-agonist peptide that has been studied in clinical trials for obesity and related metabolic conditions. It is sometimes called the “GGG tri-agonist” because it engages three hormone pathways. Importantly, retatrutide is not approved anywhere and remains experimental. This page is educational and is not medical advice; it does not recommend use.
What the research shows
Early and mid-stage clinical trials have reported effects on body weight and glucose markers in study participants. These results are reported from research settings, not established outcomes of an approved medicine, and they may change as larger trials report.
| Pathway | Proposed role |
|---|---|
| GLP-1 | Appetite and glucose signalling |
| GIP | Insulin and metabolic effects |
| Glucagon | Energy expenditure |
What people use it for (reported)
Within research and online discussion, retatrutide is reported to be of interest for weight and metabolic outcomes because of its triple-pathway design. Because it is investigational, there is no approved indication anywhere, and any reported use sits entirely outside the regulated supply chain. Material described online as “retatrutide” is not a verified, approved product, and its identity, purity and contents cannot be assumed, which is why independent testing is discussed in this community.
Things to be aware of
As an unapproved experimental compound, retatrutide’s long-term safety is not established, and the reported gastrointestinal and other effects seen in trials may not reflect what is sold informally. Reported effects on this page are not confirmed facts; they summarise what research and discussion describe. Anyone with metabolic health questions should speak with a qualified healthcare professional who can give individualised guidance. This article explains what retatrutide is and what the research so far describes; it is not an endorsement, does not recommend any dose, and does not tell anyone to obtain or use it.
Reported positives & side effects
Compiled from research and community reports. These are reported outcomes, not guarantees or medical advice, individual experiences vary widely.
Reported positives
- Reported in trials to support substantial weight reduction
- Reported to improve blood-glucose markers in study populations
- Reported strong appetite reduction via combined gut-hormone signalling
- Reported potential effects on energy expenditure from glucagon activity
Common side effects
- Reported nausea, especially during dose escalation
- Reported vomiting or diarrhoea
- Reported constipation and reduced appetite
- Reported fatigue and injection-site reactions
Rare / serious side effects
- Reported increases in heart rate in trial participants
- Theoretical pancreatitis risk shared across the GLP-class
- Reported gallbladder-related events with rapid weight loss
- Reported dehydration and electrolyte disturbance from severe GI effects
Reported misuse & overdose risks
What has been reported to happen with overuse, excessive dosing, or long-term misuse of Retatrutide. Listed so you can make an informed decision, not to suggest any use is safe.
- Because it is investigational, self-dosing outside trials is reported to risk severe dehydration and electrolyte loss when nausea, vomiting and diarrhoea go unmanaged.
- Skipping gradual dose escalation is reported to provoke intense GI effects and reports of muscle loss from inadequate intake.
- Overuse for rapid weight loss is reported to strain the gallbladder and pancreas and raise cardiovascular concern from elevated heart rate.
- Reliance on unverified research-grade vials is reported to carry dosing-error and contamination risks given no approved formulation exists.
Reported results timeline
Roughly how long people report it takes to notice effects. A general guide from reports, not a promise, and not advice. Appetite effects are reported within days, while meaningful weight changes are reported to develop over months in trial settings.
First effects
Reported appetite suppression within the first days
Noticeable change
Reported early weight and appetite changes
Clear results
Reported meaningful weight reduction in trials
Peak effect
Reported continued reduction approaching trial endpoints
Commonly reported dosing & protocol
Reported figures only, NOT a recommendation or dosing advice. These are numbers people report using, compiled for education so you can make an informed decision. We do not advise anyone to take Retatrutide. Many peptides are not approved for human use in Australia. Speak to a qualified healthcare professional.
| Route | Subcutaneous injection |
|---|---|
| Typical reported dose | Investigational and NOT approved. Trial-reported doses range roughly 1–12 mg per week, reached by gradual titration |
| Frequency | Reported as once weekly in trials |
| Cycle length | Trials run over many months with stepwise dose escalation; no established consumer cycle |
Reported reconstitution (mg → units)
Illustration only: a 10 mg vial + 1 mL bacteriostatic water = 10 mg/mL. A 4 mg dose is about 0.4 mL = 40 units on a U-100 insulin syringe.
Work out the units for your vial → CalculatorReported in trials as a once-weekly injection with gradual dose escalation over many months; framed as anecdotal and trial-derived reporting, not advice. Retatrutide is investigational and not approved by the TGA or any other regulator.
Best used with / commonly stacked with
Combinations people report using together. Reported, not recommended, stacking can increase risks.
Reported as a comparator GLP-1/GIP agonist in metabolic discussion
Reported as a comparator GLP-1 agonist for weight goals
Reported in discussion of combining incretin and amylin pathways
Safety notes
Retatrutide is an experimental compound that has not been approved as a medicine. Its full safety profile is not established and any reported gastrointestinal or other effects come from controlled trials. Anyone considering metabolic treatment should consult a qualified healthcare professional; in Australia retatrutide is not an approved product.